Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
MRNA 
Moderna Inc (MRNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/20/2025: MRNA (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 52.44% | Avg. Invested days 43 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 03/20/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 12.42B USD | Price to earnings Ratio - | 1Y Target Price 54.22 |
Price to earnings Ratio - | 1Y Target Price 54.22 | ||
Volume (30-day avg) 11133361 | Beta 1.86 | 52 Weeks Range 29.25 - 170.47 | Updated Date 03/27/2025 |
52 Weeks Range 29.25 - 170.47 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.47 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -110.04% | Operating Margin (TTM) -128.99% |
Management Effectiveness
Return on Assets (TTM) -15.14% | Return on Equity (TTM) -28.77% |
Valuation
Trailing PE - | Forward PE 32.47 | Enterprise Value 6140318040 | Price to Sales(TTM) 3.84 |
Enterprise Value 6140318040 | Price to Sales(TTM) 3.84 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 4.64 | Shares Outstanding 386623008 | Shares Floating 360000937 |
Shares Outstanding 386623008 | Shares Floating 360000937 | ||
Percent Insiders 7.27 | Percent Institutions 72.75 |
Analyst Ratings
Rating 3.31 | Target Price 73.64 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold 14 | Sell 3 | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Moderna Inc
Company Overview
History and Background
Moderna, Inc. was founded in 2010 as ModeRNA Therapeutics. It pioneered messenger RNA (mRNA) therapeutics and vaccines. Its initial focus was on developing personalized cancer vaccines. The company gained prominence during the COVID-19 pandemic with its mRNA-based vaccine.
Core Business Areas
- mRNA Therapeutics and Vaccines: Focuses on discovering, developing, and commercializing mRNA-based therapeutics and vaccines for infectious diseases, cancer, and other indications.
Leadership and Structure
Moderna is led by CEO Stu00e9phane Bancel. Its organizational structure includes research and development, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Spikevax (COVID-19 Vaccine): mRNA-based COVID-19 vaccine. Revenue in 2023 was around $6.8 billion. Competitors include Pfizer/BioNTech (PFE/BNTX), Novavax (NVAX).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and research-intensive, with a focus on developing new drugs and vaccines. It is subject to strict regulatory oversight.
Positioning
Moderna is a leading company in mRNA technology, with a first-mover advantage in mRNA vaccines. Its competitive advantage lies in its proprietary mRNA platform.
Total Addressable Market (TAM)
The global vaccine market is estimated at $59 Billion in 2024 and is expected to reach USD 96.9 Billion by 2032, growing at a CAGR of 6.5%. Moderna is well-positioned to capture a significant share of this market with its mRNA technology across various disease areas.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA Technology
- Rapid Vaccine Development Capability
- Strong Financial Position
- Established Manufacturing Capacity
Weaknesses
- Dependence on COVID-19 Vaccine Revenue
- Limited Commercial Track Record Beyond Vaccines
- Manufacturing complex mRNA products can be costly
- High dependency on partnerships
Opportunities
- Expanding mRNA Platform to New Therapies
- Developing Vaccines for Other Infectious Diseases
- Personalized Cancer Vaccines
- Strategic Partnerships and Collaborations
Threats
- Competition from Established Pharmaceutical Companies
- Patent Disputes
- Regulatory Challenges
- Declining COVID-19 Vaccine Demand
Competitors and Market Share
Key Competitors
- Pfizer (PFE)
- BioNTech (BNTX)
- Novavax (NVAX)
Competitive Landscape
Moderna competes with established pharmaceutical companies and other biotech firms. Its mRNA platform provides a competitive advantage.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Moderna experienced rapid growth during the pandemic due to its COVID-19 vaccine. However, growth has slowed as vaccine demand has decreased.
Future Projections: Analysts project revenue growth as Moderna expands its mRNA platform into new therapies. Future growth relies on pipeline execution.
Recent Initiatives: Expanding pipeline of mRNA therapeutics, investing in manufacturing capacity, and pursuing strategic partnerships.
Summary
Moderna is a pioneering mRNA therapeutics company that saw tremendous growth during the pandemic. However, the company now needs to diversify its revenue streams beyond the COVID-19 vaccine. Its strong balance sheet, and advanced mRNA technology position it well for future opportunities. Declining COVID-19 vaccine sales and competition pose significant challenges.
Similar Companies
- PFE
- BNTX
- NVAX
- LLY
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Industry Publications
- Company Website
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Moderna Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2018-12-07 | CEO & Director Mr. Stephane Bancel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5800 | Website https://www.modernatx.com |
Full time employees 5800 | Website https://www.modernatx.com | ||
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as individualized neoantigen and checkpoint adaptive immune modulation therapy; and rare disease products, including propionic and methylmalonic acidemia, glycogen storage disease type 1a, ornithine transcarbamylase deficiency, phenylketonuria, crigler-najjar syndrome type 1, and cystic fibrosis. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Generation Bio Co.; immatics N.V.; Life Edit Therapeutics; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.